JP2004531567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531567A5 JP2004531567A5 JP2002592909A JP2002592909A JP2004531567A5 JP 2004531567 A5 JP2004531567 A5 JP 2004531567A5 JP 2002592909 A JP2002592909 A JP 2002592909A JP 2002592909 A JP2002592909 A JP 2002592909A JP 2004531567 A5 JP2004531567 A5 JP 2004531567A5
- Authority
- JP
- Japan
- Prior art keywords
- stabilizers
- wetting agents
- liquid solvents
- dispersions
- suspensions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000654 additive Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Description
この薬剤は、また、通常の添加剤を含むことができる。このような添加剤は、例えば、液状溶媒、安定剤、懸濁剤、分散剤および湿潤剤である。この薬剤は、任意の所望の調合で作ることができる。例として、許容できる調合の形態は、溶液、粒体、粉体、エマルジョン、錠剤および/又は被覆錠剤等から成る。
Claims (1)
- 液状溶媒、安定剤、懸濁、分散および湿潤剤から成るグループから選択された追加の添加剤を含む請求項１乃至４のいずれか一つに記載の薬剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10125882A DE10125882B4 (de) | 2001-05-28 | 2001-05-28 | Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus |
| DE10125882.8 | 2001-05-28 | ||
| PCT/EP2002/005811 WO2002096398A2 (de) | 2001-05-28 | 2002-05-27 | Arzneimittel enthaltend einen effektor des glutathionmetabolismus zussammen mit $g(a)-liponsäure im rahmen der behandlung des diabetes mellitus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004531567A JP2004531567A (ja) | 2004-10-14 |
| JP2004531567A5 true JP2004531567A5 (ja) | 2009-08-20 |
| JP4746258B2 JP4746258B2 (ja) | 2011-08-10 |
Family
ID=7686361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592909A Expired - Fee Related JP4746258B2 (ja) | 2001-05-28 | 2002-05-27 | 薬剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7429614B2 (ja) |
| EP (2) | EP1392288B1 (ja) |
| JP (1) | JP4746258B2 (ja) |
| AT (2) | ATE429911T1 (ja) |
| AU (1) | AU2002344178A1 (ja) |
| DE (3) | DE10125882B4 (ja) |
| ES (2) | ES2322257T3 (ja) |
| PT (1) | PT1529529E (ja) |
| WO (1) | WO2002096398A2 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303229B4 (de) | 2003-01-28 | 2007-07-26 | Keyneurotek Ag | Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen |
| DE10360954B3 (de) * | 2003-12-23 | 2005-08-18 | Esparma Gmbh | Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| CA2588709C (en) * | 2004-11-24 | 2015-07-14 | Hill's Pet Nutrition, Inc. | Use of lipoic acid to improve hepatic clearance of xenobiotic substances |
| US20100099751A1 (en) * | 2008-10-21 | 2010-04-22 | Al-Mulla Fahd | Method of treating diabetes-related vascular complications |
| US20100173936A1 (en) * | 2008-12-01 | 2010-07-08 | Khan Bobby V | Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system-related disorders |
| CN116585348A (zh) * | 2021-03-23 | 2023-08-15 | 武汉广行科学研究有限公司 | 配体修饰的硫化锌纳米粒子、制备方法及其在治疗中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE904034A1 (en) * | 1989-11-09 | 1991-05-22 | Asta Medica Ag | A medicament containing r-ó-lipoic acid or s-ó-lipoic acid¹as active substance |
| DE4218572A1 (de) * | 1992-06-05 | 1993-12-09 | Asta Medica Ag | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E |
| DE4343593C2 (de) * | 1993-12-21 | 1998-05-20 | Asta Medica Ag | Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz |
| DE4420102A1 (de) * | 1994-06-09 | 1995-12-14 | Asta Medica Ag | Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen |
| GB9715444D0 (en) * | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| ES2184340T3 (es) * | 1997-12-23 | 2003-04-01 | Warner Lambert Co | Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial. |
| DE19806354B4 (de) * | 1998-02-10 | 2004-09-16 | Bdd Group Holding Ag | Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie |
| JP2000309543A (ja) * | 1999-04-28 | 2000-11-07 | Ajinomoto Co Inc | 抗糖尿病剤 |
| DE10125883A1 (de) * | 2001-05-28 | 2002-12-12 | Serumwerk Bernburg Ag | Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie |
-
2001
- 2001-05-28 DE DE10125882A patent/DE10125882B4/de not_active Expired - Fee Related
-
2002
- 2002-05-27 US US10/478,174 patent/US7429614B2/en not_active Expired - Fee Related
- 2002-05-27 AU AU2002344178A patent/AU2002344178A1/en not_active Abandoned
- 2002-05-27 EP EP02774028A patent/EP1392288B1/de not_active Expired - Lifetime
- 2002-05-27 DE DE50204093T patent/DE50204093D1/de not_active Expired - Lifetime
- 2002-05-27 EP EP04027492A patent/EP1529529B1/de not_active Expired - Lifetime
- 2002-05-27 PT PT04027492T patent/PT1529529E/pt unknown
- 2002-05-27 ES ES04027492T patent/ES2322257T3/es not_active Expired - Lifetime
- 2002-05-27 AT AT04027492T patent/ATE429911T1/de not_active IP Right Cessation
- 2002-05-27 WO PCT/EP2002/005811 patent/WO2002096398A2/de active IP Right Grant
- 2002-05-27 JP JP2002592909A patent/JP4746258B2/ja not_active Expired - Fee Related
- 2002-05-27 ES ES02774028T patent/ES2247377T3/es not_active Expired - Lifetime
- 2002-05-27 AT AT02774028T patent/ATE303145T1/de active
- 2002-05-27 DE DE50213511T patent/DE50213511D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
| WO2003087094A3 (en) | Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors | |
| HK1079448A1 (en) | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) | |
| DE602004024375D1 (de) | Carboxamidderivate | |
| CA2521509A1 (en) | Fast dissolving orally consumable films containing pharmaceutically active agents | |
| DE602005025083D1 (ja) | ||
| WO2005123093A3 (en) | Ophthalmic formulations including selective alpha 1 antagonists | |
| AU2003262262A1 (en) | Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof | |
| JP2005524658A5 (ja) | ||
| JP2007537301A5 (ja) | ||
| CL2004000788A1 (es) | Compuestos derivados de n-[2-oxo-6-(aril o heteroaril)azepan-3-il]-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxamida, antagonistas de los receptores cgrp; composicion farmaceutica; y uso del compuesto en el tratamiento del d | |
| IL179757A0 (en) | Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | |
| CA2462606A1 (en) | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer | |
| EA200700042A1 (ru) | РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА | |
| GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
| IL175220A (en) | 3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme | |
| JP2006517944A5 (ja) | ||
| DE60105448D1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
| TW200531688A (en) | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| CR20220014A (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos | |
| ATE489941T1 (de) | Nicht-lamellare zubereitungen von dioleoyl- phosphatidyl ethanolamin und polysorbat80 | |
| JP2004531567A5 (ja) | ||
| WO2003053945A3 (en) | Urea derivatives and their use as vanilloid receptor antagonists | |
| JP2005525451A5 (ja) |